Global Leading Market Research Publisher QYResearch announces the release of its latest report “HDAC8 Antibody – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global HDAC8 Antibody market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for HDAC8 Antibody was estimated to be worth US22millionin2025andisprojectedtoreachUS22millionin2025andisprojectedtoreachUS34 million by 2032, growing at a CAGR of 6.5% from 2026 to 2032. For epigenetic researchers, cancer biologists, and drug discovery scientists, the core business imperative lies in selecting HDAC8 antibodies that address the critical need for detecting and quantifying histone deacetylase 8 (HDAC8), a Class I HDAC (histone deacetylase) that removes acetyl groups from lysine residues on histones (H3, H4) and non-histone proteins (cofilin, SMC3, ARID1A), playing key roles in transcriptional regulation, cell cycle progression, chromosome cohesion, and smooth muscle contraction. HDAC8 is overexpressed in various cancers (neuroblastoma, acute myeloid leukemia (AML), non-small cell lung cancer (NSCLC), hepatocellular carcinoma, colorectal, breast, cervical) and is involved in fibrosis (pulmonary, liver), Cornelia de Lange syndrome (CdLS (Cornelia de Lange syndrome)), and heart disease. HDAC8 inhibitors (PCI-34051, ITSA-1) are being developed as targeted therapies. HDAC8 antibody (rabbit polyclonal, mouse/rabbit monoclonal) is validated for Western Blot (WB), Immunohistochemistry (IHC), Immunofluorescence (IF), Immunoprecipitation (IP), ChIP (chromatin immunoprecipitation), and ELISA. Applications: epigenetics (histone acetylation), cancer biology (oncogene validation), neuroblastoma research, Cornelia de Lange syndrome studies.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/releases/5985638/hdac8-antibody
The HDAC8 Antibody market is segmented as below:
GeneTex
Thermo Fisher Scientific
Aviva Systems Biology
BosterBio
Biorbyt
Merck
RayBiotech
EpiGentek
LifeSpan BioSciences
NSJ Bioreagents
OriGene Technologies
Novus Biologicals
ProSci
Abcam
Bioss
HUABIO
BioLegend
Elabscience Biotechnology
Affinity Biosciences
ABclonal Technology
Santa Cruz Biotechnology
Jingjie PTM BioLab
Wuhan Fine Biotech
Segment by Type
Monoclonal
Polyclonal
Segment by Application
Immunochemistry (IHC)
Immunofluorescence (IF)
Immunoprecipitation (IP)
Western Blot (WB)
ELISA
Others
1. Market Drivers: Epigenetics Funding, Cancer Target Discovery, and Neuroblastoma Research
Several powerful forces are driving the HDAC8 antibody market:
Epigenetics and chromatin regulation – HDAC8 deacetylates histones (H3K9ac, H3K27ac, H4K16ac). Antibody for ChIP-seq (chromatin immunoprecipitation sequencing) to map genomic binding, histone acetylation changes. NIH (National Institutes of Health), Wellcome Trust, Horizon 2020 funding.
Neuroblastoma and pediatric cancer – HDAC8 is a validated therapeutic target for neuroblastoma (childhood cancer). HDAC8 inhibitors (PCI-34051) induce differentiation, apoptosis. Antibody for IHC, WB expression.
Cancer stem cells and drug resistance – HDAC8 expression in cancer stem cells, chemotherapy resistance. Antibody for functional studies.
Recent market data (December 2025): According to Global Info Research analysis, polyclonal HDAC8 antibodies dominate with approximately 65% revenue share (rabbit polyclonal, higher sensitivity, faster development). Monoclonal 35% share (superior specificity, batch consistency, ChIP-grade). Western Blot (WB) largest application (40% share) (expression, siRNA/shRNA knockdown validation). Immunohistochemistry (IHC) 25% share (tissue localization, tumor grading). Immunoprecipitation (IP) 15% share (protein-protein interaction, complex purification). ChIP (in Others) 10% share (chromatin binding). Immunofluorescence (IF) 5% share. ELISA 5% share. North America largest market (45% share). Europe 30% share. Asia-Pacific 20% share. Abcam, Cell Signaling Technology (CST) (not listed), Santa Cruz, GeneTex, Novus, Proteintech (not listed), Thermo Fisher leading suppliers.
2. Antibody Types and Specifications
| Type | Host | Clonality | Specificity | Sensitivity | Batch Consistency | Price | Share |
|---|---|---|---|---|---|---|---|
| Polyclonal | Rabbit | Polyclonal (serum) | Human, mouse, rat | High | Variable | US$200-450 | ~65% |
| Monoclonal | Mouse, rabbit | Monoclonal (hybridoma) | Human (specific) | High | Excellent | US$300-600 | ~35% |
Key specifications: Target (HDAC8, histone deacetylase 8, HD8, RPD3). Host (rabbit, mouse). Reactivity (human, mouse, rat). Applications validated (WB, IHC (FFPE, frozen), IF, IP, ChIP, ELISA). Concentration (1 mg/mL). Format (liquid, lyophilized, conjugated (HRP, Biotin, FITC, Alexa Fluor)). Storage (-20°C). Recommended dilution (WB 1:500-1:2000, IHC 1:100-1:500, ChIP 1:50-1:200). Positive control (HeLa, HEK293T, A549, MCF7, SK-N-AS (neuroblastoma) lysate). Polyclonal (Abcam ab187139, CST #2416); Monoclonal (Abcam ab197044, CST #46007, Santa Cruz sc-376042).
Exclusive observation (Global Info Research analysis): HDAC8 antibody market is dominated by Abcam, Cell Signaling Technology (CST), Santa Cruz Biotechnology (SCBT), and European, US brands. Polyclonal rabbit antibodies (CST #2416, Abcam ab187139) widely used for WB, IHC. Monoclonal mouse antibodies (Santa Cruz sc-376042) also common. Chinese suppliers (Bioss, HUABIO, Elabscience, Affinity, ABclonal, Jingjie, Wuhan Fine) lower cost (30-50% less), expanding export. ChIP-grade HDAC8 antibody (CST #46007) validated for ChIP-seq.
User case – Western Blot (December 2025): Cancer research lab (US) validates HDAC8 knockdown in neuroblastoma cell line (SK-N-AS) using siRNA. RIPA lysate, SDS-PAGE, transfer, primary antibody (CST #2416 rabbit polyclonal, 1:1000), secondary anti-rabbit HRP. Detection ECL (Enhanced Chemiluminescence). Loading control β-actin.
User case – Immunohistochemistry (IHC) (January 2026): Pathology lab (China) stains hepatocellular carcinoma (HCC) tissue array for HDAC8 (prognosis). FFPE sections, antigen retrieval (citrate), primary antibody (Abcam rabbit monoclonal (EPR16040), 1:200), secondary HRP polymer, DAB detection. Scoring nuclear/cytoplasmic staining.
3. Technical Challenges
Cross-reactivity with other Class I HDACs (HDAC1, 2, 3) – HDAC8 shares homology with HDAC1/2/3. Antibody specificity validation (knockdown, peptide blocking, immunodepletion). Monoclonal preferable.
ChIP-seq validation – ChIP-grade antibody must immunoprecipitate chromatin specifically (low background, reproducible peaks). Validated by manufacturer.
Technical difficulty – Antibody lot-to-lot variability (polyclonal): Polyclonal variable between lots. Bulk purchase, recombinant monoclonal improvement.
Technical development (October 2025): CST (Cell Signaling Technology) introduced rabbit monoclonal HDAC8 antibody (clone D6G6) for ChIP-seq, IHC, IF, WB. Recombinant production, high batch consistency. Price US$400 per 100µL.
4. Competitive Landscape
Key players include: GeneTex (US), Thermo Fisher Scientific (US), Aviva Systems Biology (US), BosterBio (US), Biorbyt (UK), Merck (Germany), RayBiotech (US), EpiGentek (US), LifeSpan BioSciences (US), NSJ Bioreagents (US), OriGene Technologies (US), Novus Biologicals (US), ProSci (US), Abcam (UK), Bioss (China), HUABIO (China), BioLegend (US), Elabscience Biotechnology (China), Affinity Biosciences (China), ABclonal Technology (US/China), Santa Cruz Biotechnology (US), Jingjie PTM BioLab (China), Wuhan Fine Biotech (China). Abcam, CST, Santa Cruz leaders.
Regional dynamics: North America (Abcam US, CST, Santa Cruz, Novus, GeneTex, Thermo Fisher) largest market. Europe (Abcam UK, Bio-Rad (not listed), Biorbyt). China (Bioss, HUABIO, Elabscience, Affinity, ABclonal, Jingjie) domestic.
5. Outlook
HDAC8 antibody market will grow at 6.5% CAGR to US$34 million by 2032, driven by epigenetics research (ChIP-seq), cancer target validation (neuroblastoma, AML), and HDAC inhibitor development. Technology trends: recombinant monoclonal (consistency, ChIP-validated), CUT&Tag (cleavage under targets and tagmentation) compatible, and spatial proteomics (imaging mass cytometry). Asia-Pacific growth 7-8% CAGR.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
